Related Experiment Video

Updated: Nov 8, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.4K

HER2-targeted therapies in gastric cancer

Yinxing Zhu1, Xuedan Zhu1, Xiaowei Wei1

  • 1Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.

Biochimica Et Biophysica Acta. Reviews on Cancer
|April 24, 2021
PubMed

Insights

Trastuzumab is the only approved HER2-targeted drug for advanced gastric cancer. This review summarizes novel anti-HER2 agents and strategies to overcome resistance in HER2-positive gastric cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The human epidermal growth factor receptor-2 (HER-2) signaling pathway is a key target in cancer therapy.
  • Trastuzumab is the sole FDA-approved HER2-targeted drug for first-line treatment of HER2-positive advanced gastric cancer, highlighting a gap in treatment options.

Purpose of the Study:

  • To review recent advancements in anti-HER2 agents for gastric cancer.
  • To explore mechanisms of resistance to HER2-targeted therapy in HER2-positive gastric cancer.
  • To discuss future strategies for overcoming resistance and novel therapeutic approaches.

Main Methods:

  • Literature review of recent clinical research and development of anti-HER2 agents.
  • Analysis of mechanisms contributing to resistance against HER2-targeted therapies.
  • Discussion of emerging therapeutic strategies and novel drug development.

Main Results:

  • Several novel HER2-targeted drugs are under development, including small molecular kinase inhibitors, antibody-drug conjugates, and other novel therapies.
  • Mechanisms of resistance to HER2-targeted therapy are complex and multifactorial.
  • Promising strategies to overcome resistance and new therapeutic approaches are being investigated.

Conclusions:

  • There is a significant need for novel HER2-targeted therapies beyond trastuzumab for gastric cancer.
  • Understanding and overcoming resistance mechanisms are crucial for improving patient outcomes.
  • Ongoing research into novel anti-HER2 agents and combination strategies holds promise for future treatment of HER2-positive gastric cancer.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.3K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

955

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.3K
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
695
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
213
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
813